Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Gemcitabine and Cisplatin in Pancreatic Cancer
NCT00758381Phase 2Unknown
- Sponsor
- Fondazione Giscad per la Ricerca sui Tumori
- Start
- Aug 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in pancreatic cancer (PC) (2 arms), sponsored by Fondazione Giscad per la Ricerca sui Tumori. Primary endpoint: Progression Free Survival. Status: unknown.
02
Drugs
sorafenib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00758381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758381.